Emerging evidence suggests that DOACs are likely to replace low molecular weight heparin as the standard of care for cancer-related thrombosis, with the possible exception of patients with GI cancer, an international experts says. Speaking at the Blood 2019 meeting in Perth, Professor John Eikelboom, a haematologist from McMaster University in Canada, told delegates that ...
DOACs could become standard of care in cancer-related VTE: expert
By Nicola Garrett
30 Oct 2019